Physician profile
Parth S Patel
NPI 1447744453
$45,678.97
in general payments reported to CMS, 2019-2025
26 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,172 · 2022: $1,175 · 2023: $871 · 2024: $14K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $11K · Travel and Lodging: $2,781 · Consulting Fee: $2,113 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,726.00 |
| Food and Beverage | $10,543.94 |
| Travel and Lodging | $2,781.30 |
| Consulting Fee | $2,112.50 |
| Education | $167.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $36,066.18 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,670.23 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $1,233.85 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $837.91 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $767.66 | 2021-2025 | |
| Lilly USA, LLC | $718.72 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $610.30 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $593.74 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $558.57 | 2021-2025 | |
| Ucb, INC. | $402.13 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $320.59 | 2024 | Vtama |
| Amgen INC. | $307.12 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $303.04 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $279.03 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $245.45 | 2022-2025 | Tremfya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $186.20 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $150.28 | 2023-2024 | Nuzyra |
| Botanix Sb INC | $136.30 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $74.57 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $55.92 | 2024-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.53 | 2024-2025 | Spevigo |
| Pfizer INC. | $36.17 | 2025 | |
| Cipher Pharmaceuticals US LLC | $29.90 | 2025 | Spinosad, Natroba |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.71 | 2025 | Cabtreo |
| Sanofi-Aventis U.S. LLC | $15.47 | 2021 | |
| Journey Medical Corporation | $15.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.